Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of human PARP. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human PARP. Methods of using these compounds for modulation of human PARP expression and for treatment of diseases associated with expression of human PARP are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of WRN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding WRN. Methods of using these compounds for modulation of WRN expression and for treatment of diseases associated with expression of WRN are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p40 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p40 subunit. Methods of using these compounds for modulation of Interleukin 12 p40 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p40 subunit are provided.

Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human Her-1. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding Her-1. Methods of using these oligonucleotides for inhibition of Her-1 expression and for treatment of diseases such as cancers associated with overexpression of Her-1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-beta. Methods of using these compounds for modulation of Casein kinase 2-beta expression and for treatment of diseases associated with expression of Casein kinase 2-beta are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cellular apoptosis susceptibility gene. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cellular apoptosis susceptibility gene. Methods of using these compounds for modulation of cellular apoptosis susceptibility gene expression and for treatment of diseases associated with expression of cellular apoptosis susceptibility gene are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glioma-associated oncogene-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glioma-associated oncogene-2. Methods of using these compounds for modulation of glioma-associated oncogene-2 expression and for treatment of diseases associated with expression of glioma-associated oncogene-2 are provided.

Abstract: Probes and processes for their use for specific recognition and/or cleavage of double-stranded DNA or RNA at sequence specific desired loci through the intermediacy of a triple helix are disclosed. These probes may also be used as diagnostic chemotherapeutic agents through incorporation of a radiolabeled, fluorescing, or otherwise detectable molecule. Preferred assay conditions are also provided for recognition of homopurine-homopyrimidine double-helical tracts within large DNA by triple helix formation under physiological conditions. Hybridization probes for double-stranded recognition with binding site sizes that range >8 base pairs are also provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of calreticulin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding calreticulin. Methods of using these compounds for modulation of calreticulin expression and for treatment of diseases associated with expression of calreticulin are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RIP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RIP2. Methods of using these compounds for modulation of RIP2 expression and for treatment of diseases associated with expression of RIP2 are provided.

Abstract: The present invention provides novel anticode oligomers and methods of using them for controlling the growth of cancer cells expressing the bcl-2 gene.

Abstract: This invention provides compositions and methods for modulating expression of members of the human Rho gene family, which encode low molecular weight GTPases that act as molecular switches in signal transduction. In preferred embodiments, Rho family members include RhoA, RhoB, RhoC, RhoG, Rac1 and cdc42. This invention is also directed to methods for inhibiting hyperproliferation of cells; these methods can be used diagnostically or therapeutically. Furthermore, this invention is directed to treatment of conditions associated with expression of the human Rho family members, particularly in hyperproliferative disorders.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Tumor Necrosis Factor Receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Tumor Necrosis Factor Receptor 2. Methods of using these compounds for modulation of Tumor Necrosis Factor Receptor 2 expression and for treatment of diseases associated with expression of Tumor Necrosis Factor Receptor 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group VI (Ca2+-independent). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group VI (Ca2+-independent). Methods of using these compounds for modulation of Phospholipase A2, group VI (Ca2+-independent) expression and for treatment of diseases associated with expression of Phospholipase A2, group VI (Ca2+-independent) are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p35 subunit are provided.

Abstract: A method for regulating the production level of a desired protein in a transformed mammalian cell, comprising: a directly amplifiable gene sequence, in expressable form, which when expressed renders said cell more resistant to a toxic agent; a gene of interest, in expressible form, which encodes a desired protein foreign to said cell; and an anti-sense gene sequence, in transcribable form, encoding an anti-sense RNA capable of selectively hybridizing to at least a portion of the mRNA transcribed from said directly amplifiable gene sequence so as to inhibit the translation of said mRNA, such that a higher level of amplification of said directly amplifiable gene and said gene of interest can be achieved, if the cell is exposed to a sufficient level of the toxic agent, that in the absence of said anti-sense RNA.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BCAS1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCAS1. Methods of using these compounds for modulation of BCAS1 expression and for treatment of diseases associated with expression of BCAS1 are provided.

Abstract: The invention provides a number of strategies for transferring and/or evolving gene(s) associated with cellular DNA uptake so that they confer or enhance DNA-uptake capacity of a recipient cell. Evolution is achieved by recursive cycles of recombination and screening/selection. One such strategy entails evolving genes that confer competence in one species to confer either greater competence in that species, or comparable or greater competence in a second species. Another strategy entails evolving genes for use as components of cloning vector to confer enhanced uptake of the vector. Other strategies entail evolving viral receptors, viruses, and genes that mediate conjugal transfer.

Abstract: The invention provides isolated adenosine deaminase (ADA) nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering ADA concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.